Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Botanix Pharmaceuticals Limited (ASX: BOT) today provided investors with an update on its suite of cannabis-derived clinical trials that target dermatological and antimicrobial conditions. In addition to this, the company has provided its roadmap, outlining how Botanix will be moving forward amid the COVID-19 crisis.
Click HERE to read the article on The Green Fund.